Vaxxas Archives - Medical Design Sourcing

Vaxxas wins $3.7M award to support needle-free typhoid vaccine tech

Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]Vaxxas announced that it received a $3.67 million award to conduct studies of a typhoid vaccine delivered by its needle-free device.

The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to the skin as a patch, the system rapidly delivers vaccines to immune cells below the skin surface.

HD-MAP offers improved thermostability, potentially reducing the cost and complexity of cold-chain distribution and storage. It also potentially requires less training to administer and could even lead to self-administration.

Get the full story at our sister site, Drug Delivery Business News.

Vaxxas raises $23M for needle-free drug delivery tech

Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]Vaxxas announced today that it completed a financing round that brings in $23 million (A$34 million) in new funds.

Existing investors OneVentures and UniQuest led the round. New investors, including members of the Vaxxas board and management team, along with individual investors, participated. The company earmarked proceeds to advance its clinical programs, including its needle-free COVID-19 vaccine candidate.

Other potential uses include the installation of the company’s first manufacturing lines. These would offer the capacity to support Vaxxas’ first products through late-stage clinical studies and early commercial production.

Get the full story at our sister site, Drug Delivery Business News.

Vaxxas receives more than $5 million grant for vaccine delivery patch

Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device.

Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant represents part of the Australian government’s Modern Manufacturing Initiative (MMI). Funding supports the manufacturing scale-up of Vaxxas’ device for applying vaccines to the skin using a small patch.

Get the full story at our sister site, Drug Delivery Business News.

Vaxxas licenses COVID-19 vaccine for patch delivery system, expects to finish Phase 1 trial this year

Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]Vaxxas announced today that it was granted an exclusive license to a next-generation COVID-19 vaccine for use with its delivery patch.

Cambridge, Massachusetts-based Vaxxas received the exclusive license from The University of Texas at Austin for its HexaPro SARS-CoV-2 spike subunit vaccine.

Get the full story at our sister site, Drug Delivery Business News.

Merck eyes tiny patches as a vaccine delivery method

Vaxxas’ High Density Microarray Patches (HD-MAP)

Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today.

The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans to acquire vaccine developer Themis Bioscience. Vaxxas (Cambridge, Mass.; Brisbane, Australia) notes that any vaccine could be delivered with its dime-sized patch.

Also today, Vaxxas announced that German manufacturing equipment maker Harro Höfliger will help Vaxxas develop a high-throughput, aseptic manufacturing line to make vaccine products based on Vaxxas’ HD-MAP technology — with a goal of eventually churning out millions of vaccine patches a week.

Get the full story on our …

Merck eyes tiny patches as a vaccine delivery method

Vaxxas’ High Density Microarray Patches (HD-MAP)

Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today.

The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans to acquire vaccine developer Themis Bioscience. Vaxxas (Cambridge, Mass.; Brisbane, Australia) notes that any vaccine could be delivered with its dime-sized patch.

“We are excited by this latest milestone in our collaboration with Merck, an early adopter of our novel HD-MAP platform,” Vaxxas CEO David L. Hoey said in a news release. “With their strong legacy of vaccine development Merck is a tremendous partner in our efforts to enhance the efficiency, effectiveness, and reach of v…